Capienda is developing an advanced bioanalytical technology to accelerate drug discovery in the pharmaceutical industry.
Capienda’s drug delivery technology is designed to target disease-relevant cells (while avoiding normal cells) and engages previously un-druggable targets. Programs for anti-inflammatory therapy are under development.
COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES, US Provisional Patent Application No. 62/651,621 (filed April 2, 2018).